Statin-associated myopathy with normal creatine kinase levels

被引:418
作者
Phillips, PS
Haas, RH
Bannykh, S
Hathaway, S
Gray, NL
Kimura, BJ
Vladutiu, GD
England, JDF
机构
[1] Scripps Mercy Hosp, San Diego, CA 92103 USA
[2] Univ Calif San Diego, Ctr Med, San Diego, CA 92103 USA
[3] SUNY Buffalo, Buffalo, NY 14260 USA
关键词
D O I
10.7326/0003-4819-137-7-200210010-00009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Muscle symptoms in patients who are treated with statins and have normal creatine kinase levels are not well understood. Objective: To report biopsy-confirmed myopathy and normal creatine kinase levels associated with statin use. Design: Case reports from preliminary analysis of an ongoing clinical trial. Setting: Clinical research center in a community hospital. Patients: Four patients with muscle symptoms that developed during statin therapy and reversed during placebo use. Measurements: 1) Patients' ability to identify blinded statin therapy and 2) standard measures of functional capacity and muscle strength. Results: All four patients repeatedly distinguished blinded statin therapy from placebo. Strength testing confirmed weakness during statin therapy that reversed during placebo use. Muscle biopsies showed evidence of mitochondrial dysfunction, including abnormally increased lipid stores, fibers that did not stain for cytochrome oxidase activity, and ragged red fibers. These findings reversed in the three patients who had repeated biopsy when they were not receiving statins. Creatine kinase levels were normal in all four patients despite the presence of significant myopathy. Conclusion: Some patients who develop muscle symptoms while receiving statin therapy have demonstrable weakness and histopathologic findings of myopathy despite normal serum creatine kinase levels.
引用
收藏
页码:581 / 585
页数:5
相关论文
共 19 条
[1]  
Dubowitz V., 1985, MUSCLE BIOPSY PRACTI
[2]   MITOCHONDRIAL MYOPATHY DEVELOPING ON TREATMENT WITH THE HMG COA REDUCTASE INHIBITORS - SIMVASTATIN AND PRAVASTATIN [J].
ENGLAND, JDF ;
WALSH, JC ;
STEWART, P ;
BOYD, I ;
ROHAN, A ;
HALMAGYI, GM .
AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1995, 25 (04) :374-375
[3]   Learning from the cerivastatin experience [J].
Farmer, JA .
LANCET, 2001, 358 (9291) :1383-1385
[4]   Lipid-lowering drugs and risk of myopathy:: A population based follow-up study [J].
Gaist, D ;
Rodríguez, LAG ;
Huerta, C ;
Hallas, J ;
Sindrup, SH .
EPIDEMIOLOGY, 2001, 12 (05) :565-569
[5]   Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin [J].
Gruer, PJK ;
Vega, JM ;
Mercuri, MF ;
Dobrinska, MR ;
Tobert, JA .
AMERICAN JOURNAL OF CARDIOLOGY, 1999, 84 (07) :811-815
[6]   Comparison of the Bayesian approach and a simple algorithm for assessment of adverse drug events [J].
Lanctot, KL ;
Naranjo, CA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 58 (06) :692-698
[7]   THE EFFICACY OF MANUAL ASSESSMENT OF MUSCLE STRENGTH USING A NEW DEVICE [J].
MARINO, M ;
NICHOLAS, JA ;
GLEIM, GW ;
ROSENTHAL, P ;
NICHOLAS, SJ .
AMERICAN JOURNAL OF SPORTS MEDICINE, 1982, 10 (06) :360-364
[8]   IN-VITRO MYOTOXICITY OF THE 3-HYDROXY-3-METHYLGLUTARYL COENZYME-A REDUCTASE INHIBITORS, PRAVASTATIN, LOVASTATIN, AND SIMVASTATIN, USING NEONATAL RAT SKELETAL MYOCYTES [J].
MASTERS, BA ;
PALMOSKI, MJ ;
FLINT, OP ;
GREGG, RE ;
WANGIVERSON, D ;
DURHAM, SK .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1995, 131 (01) :163-174
[9]   Myopathy induced by HMG-CoA reductase inhibitors in rabbits: A pathological, electrophysiological, and biochemical study [J].
Nakahara, K ;
Kuriyama, M ;
Sonoda, Y ;
Yoshidome, H ;
Nakagawa, H ;
Fujiyama, J ;
Higuchi, I ;
Osame, M .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1998, 152 (01) :99-106
[10]   MUSCLE COENZYME-Q DEFICIENCY IN FAMILIAL MITOCHONDRIAL ENCEPHALOMYOPATHY [J].
OGASAHARA, S ;
ENGEL, AG ;
FRENS, D ;
MACK, D .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (07) :2379-2382